natgillin/translations-raw huggingface dataset:
Victrelis may be used in adults who are previously untreated for HCV infection or who have previously used medicines called ‘interferons’ and ‘pegylated interferons’.
Victrelis se može primjenjivati u odraslih osoba koje prethodno nisu liječile HCV infekciju kao i u onih koji su ranije koristili lijekove koji se nazivaju "interferonima" i "pegiliranim interferonima".
Victrelis must not be administered in the absence of peginterferon alfa and ribavirin.
Victrelis se ne smije primijeniti bez peginterferona alfa i ribavirina.
Victrelis or rilpivirine is
prilagođavati dozu lijeka
Victrelis should be
Victrelis treba nadzirati na
Victrelis with an oral
primjena lijeka Victrelis i
Victrelis, in combination with peginterferon alfa and ribavirin, is contraindicated when co- administered with medicines that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events such as orally administered midazolam and triazolam, bepridil, pimozide, lumefantrine, halofantrine, tyrosine kinase inhibitors, simvastatin, lovastatin, quetiapine, alfuzosin, silodosin, and ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine) (see section 4.3).
Victrelis u kombinaciji s peginterferonom alfa i ribavirinom kontraindiciran je ako se istodobno primjenjuju lijekovi čiji se klirens velikim dijelom odvija putem CYP3A4/5 i kod kojih su povišene koncentracije u plazmi povezane s ozbiljnim i/ili po život opasnim nuspojavama - kao što su peroralno primijenjeni midazolam i triazolam, bepridil, pimozid, lumefantrin, halofantrin, inhibitori tirozin kinaze, simvastatin, lovastatin, kvetiapin, alfuzosin, silodosin i derivati ergota (dihidroergotamin, ergonovin, ergotamin, metilergonovin) (vidjeti dio 4.3).
Victrelis- PR48 (N=161)
Victrelis- PR48 (N= 161)
Victrelis- RGT (N=162)
Victrelis- RGT (N= 162)
Victrelis.
lijekom Victrelis.
Victrelis.
s lijekom Victrelis.
Vidaza 25 mg/mL powder for suspension for injection
Vidaza 25 mg/mL prašak za suspenziju za injekciju
Vidaza contains the active substance ‘azacitidine’.
Vidaza sadržava djelatnu tvar azacitidin.
Vidaza is a white powder for suspension for injection and is supplied in a glass vial containing 100 mg of azacitidine.
Vidaza je bijeli prašak za suspenziju za injekciju pohranjen u staklenoj bočici koja sadrži 100 mg azacitidina.
Vidaza is an anti-cancer agent which belongs to a group of medicines called ‘anti-metabolites’.
Vidaza je lijek protiv raka i pripada skupini lijekova koji se zovu „antimetaboliti“.
Vidaza is given every day for one week, followed by a rest period of 3 weeks.
Vidaza se primjenjuje svakoga dana tijekom jednog tjedna, nakon čega slijedi razdoblje stanke od 3 tjedna.
Vidaza is not recommended for use in children and adolescents below the age of 18.
Ne preporučuje se primjena Vidaze u djece i adolescenata mlađih od 18 godina.
Vidaza is used for the treatment of adults with the following diseases, if they cannot have haematopoietic stem cell transplantation (when the patient receives stem cells to restore the bone marrow’s ability to produce healthy blood cells): myelodysplastic syndromes, a group of conditions where too few blood cells are produced by the bone marrow.
Lijek Vidaza koristi se za terapiju odraslih osoba sa sljedećim bolestima, ako se ne mogu podvrgnuti transplantaciji hematopoetskih matičnih stanica (kada bolesnik primi matične stanice kako bi se obnovila sposobnost koštane srži da proizvodi zdrave krvne stanice): mijelodisplastičnim sindromima, grupom stanja u kojima koštana srž proizvodi premalo krvnih stanica.
Vidaza is used in adults who are not able to have a stem cell transplantation to treat: higher-risk myelodysplastic syndromes (MDS). chronic myelomonocytic leukaemia (CMML). acute myeloid leukaemia (AML).
Vidaza se primjenjuje kod odraslih kojima se ne mogu transplantirati matične stanice za liječenje: mijelodisplastičnih sindroma (MDS) visokog rizika kronične mijelomonocitne leukemije (KMML) akutne mijeloične leukemije (AML)
Vidaza is used in patients with an intermediate to high risk of progressing to AML or death; chronic myelomonocytic leukaemia (CMML, a cancer affecting white blood cells called monocytes).
Vidaza se koristi u bolesnika sa srednjim do visokim rizikom progresije do AML-a ili smrti; kroničnom mijelomonocitnom leukemijom (CMML-om, tipom raka koji zahvaća bijele krvne stanice zvane monociti).
Viekirax
Ovaj režim
Viekirax
Viekirax bez
Viekirax
Viekirax s
Viekirax
Viekirax s dasabuvirom
Viekirax
Viekirax sa
Viekirax +
ili bez njega
Viekirax 12.5 mg/75 mg/50 mg film-coated tablets ombitasvir/paritaprevir/ritonavir
Viekirax 12,5 mg/75 mg/50 mg filmom obložene tablete ombitasvir/paritaprevir/ritonavir
Viekirax and dasabuvir
Viekirax i dasabuvir
Viekirax and dasabuvir (12 weeks)
Viekirax i dasabuvir (12 tjedana)
Viekirax and dasabuvir for 12 weeks
Viekirax i dasabuvir tijekom 12 tjedana
Viekirax and dasabuvir with RBV
Viekirax i dasabuvir s RBV
Viekirax and dasabuvir with RBV for 12
Viekirax i dasabuvir s RBV-om tijekom
Viekirax and dasabuvir with RBV for 12 weeks
Viekirax i dasabuvir s RBV-om tijekom 12 tjedana
Viekirax can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in managing patients with chronic hepatitis C.
Viekirax se izdaje samo na liječnički recept, a liječenje treba započeti i nadzirati liječnik iskusan u liječenju bolesnika oboljelih od kroničnog hepatitisa C.
Viekirax has been shown to be effective against genotypes 1a and 1b and genotype 4.
Lijek Viekirax pokazao se djelotvornim protiv genotipova 1a i 1b te genotipa 4.
Viekirax has not been studied in HCV-infected patients on dialysis.
Viekirax nije ispitivan u bolesnika s infekcijom HCV-om na dijalizi.
Viekirax is always used in combination with other medicines for chronic hepatitis C, such as dasabuvir and ribavirin.
Viekirax se uvijek koristi u kombinaciji s drugim lijekovima za liječenje kroničnog hepatitisa C, poput dasabuvira i ribavirina.
Viekirax is an antiviral medicine used in combination with other medicines to treat adults with chronic (long-term) hepatitis C, an infectious disease of liver caused by the hepatitis C virus.
Viekirax je protuvirusni lijek koji se koristi u kombinaciji s drugim lijekovima za liječenje kroničnog (dugotrajnog) hepatitisa C, infektivne bolesti jetre koju uzrokuje virus hepatitisa C u odraslih osoba.
Viekirax is an antiviral medicine used to treat adults with chronic (long-term) hepatitis C (an infectious disease that affects the liver, caused by the hepatitis C virus).
Viekirax je antivirusni lijek koji se koristi za liječenje odraslih koji boluju od kroničnog (dugotrajnog) hepatitisa C (infektivna bolest jetre koju izaziva virus hepatitisa C).
Viekirax is contraindicated in patients with severe hepatic impairment (Child-Pugh C) (see sections 4.2, 4.3, 4.8 and 5.2).
Viekirax je kontraindiciran u bolesnika s teškim oštećenjem jetrene funkcije (Child-Pugh stadij C) (vidjeti dijelove 4.2, 4.3, 4.8 i 5.2).
Viekirax is contraindicated in patients with severe hepatic impairment (Child-Pugh C) (see sections 4.3 and 5.2).
Viekirax je kontraindiciran u bolesnika s teškim oštećenjem jetrene funkcije (Child-Pugh stadij C) (vidjeti dijelove 4.3 i 5.2).
Viekirax is not recommended for administration as monotherapy and must be used in combination with other medicinal products for the treatment of hepatitis C infection (see sections 4.2 and 5.1).
Ne preporučuje se primjena lijeka Viekirax kao monoterapije te se za liječenje infekcije hepatitisom C mora propisivati u kombinaciji s drugim lijekovima (vidjeti dijelove 4.2 i 5.1).
Viekirax is not recommended in patients with moderate hepatic impairment (Child-Pugh B).
Ne preporučuje se primjena lijeka Viekirax u bolesnika s umjerenim oštećenjem jetrene funkcije (Child-Pugh stadij B).
Viekirax must not be used in patients with severe liver impairment and in women taking ethinylestradiol, an oestrogen found in hormonal contraceptives.
Viekirax se ne smije primjenjivati u bolesnika s ozbiljnim oštećenjem jetre i žena koje uzimaju etinilestradiol, estrogen koji je prisutan u hormonalnim kontracepcijskim sredstvima.
Viekirax safety and efficacy have been established in combination with dasabuvir and/or ribavirin.
Ustanovljene su sigurnost i djelotvornost lijeka Viekirax u kombinaciji s dasabuvirom i/ili ribavirinom.
Viekirax should not be used during pregnancy or in women of childbearing potential not using effective contraception.
Lijek Viekirax se ne smije uzimati u trudnoći niti ga smiju uzimati žene u reproduktivnoj dobi bez da koriste učinkovitu metodu kontracepcije.
Viekirax tablets are pink, oblong film-coated tablets of dimmensions 18.8 mm x 10.0 mm, marked with ‘AV1’.
Viekirax tablete su ružičaste, duguljaste filmom obložene tablete, dimenzija 18,8 mm x 10,0 mm s oznakom 'AV1'.
Viekirax with and without
lijekom s dasabuvirom ili
Viekirax with and without dasabuvir
Viekirax s dasabuvirom ili bez njega
Viekirax with or without
dasabuvirom ili bez njega.
Viekirax with or without
Viekirax s
Viekirax with or without dasabuvir.
dasabuvirom ili bez njega.
Viekirax with ribavirin & without dasabuvir was evaluated for 12 weeks in genotype 1 treatment naive and treatment experienced non-cirrhotic subjects in a phase 2 study M11-652 (AVIATOR).
Liječenje lijekom Viekirax s ribavirinom i bez dasabuvira ispitivalo se tijekom 12 tjedana u prethodno liječenih te prethodno neliječenih ispitanika s infekcijom genotipom 1 bez ciroze u ispitivanju faze II M11-652 (AVIATOR).
Viekirax without
Viekirax bez dasabuvira
Viekirax, give one fifth of the total daily dose of ciclosporin once daily with Viekirax.
lijekom Viekirax, primijeniti jednu petinu ukupne dnevne doze ciklosporina jedanput na dan s lijekom Viekirax.
Viekirax, when co-administered with dasabuvir, combines three direct-acting antiviral agents with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral lifecycle.
Viekirax primijenjen zajedno s dasabuvirom kombinira tri antivirotika s izravnim djelovanjem koji imaju različite mehanizme djelovanja i profile rezistencije koji se međusobno ne preklapaju, što omogućuje ciljano djelovanje na HCV u nekoliko različitih stadija životnog ciklusa virusa.
View your pen here
Ovdje pregledajte svoju brizgalicu
Viewing window
Kontrolni prozorčić
Viewing Window
Prozor za provjeru
Viewing window
Prozorčić za provjeru lijeka
Vifor Fresenius Medical Care Renal Pharma France 100-101 Terrasse Boieldieu
Vifor Fresenius Medical Care Renal Pharma France 100­101 Terrasse Boieldieu
Vigabatrin/efavirenz
Vigabatrin/efavirenz Gabapentin/efavirenz
Vigabatrin/Efavirenz Gabapentin/Efavirenz
fluoksetin/efavirenz
Vigabatrin/Tenofovir disoproxil fumarate Gabapentin/Tenofovir disoproxil fumarate
vigabatrin/tenofovirdizoproksil fumarat gabapentin/tenofovirdizoproksil fumarat
Vigilance for skin lesions is warranted and a medical evaluation of the skin is recommended at initiation, after at least one year and then at least yearly taking into consideration clinical judgement.
Potrebno je pomno pratiti pojavu kožnih lezija, te se preporučuje provesti pregled kože na početku uzimanja lijeka, najkasnije nakon godinu dana, a zatim najmanje jednom godišnje prema kliničkoj prosudbi.
Vigilance for the timely detection of serious infection is recommended for patients receiving biological treatments for moderate to severe RA as signs and symptoms of acute inflammation may be lessened, associated with suppression of the acute phase reactants.
Kod bolesnika koji primaju biološke lijekove za liječenje umjerenog do teškog oblika RA preporučuje se povećan oprez kako bi se na vrijeme otkrila prisutnost ozbiljne infekcije, budući da znakovi i simptomi akutne upale mogu biti ublaženi zbog supresije reaktanata akutne faze.
ViiV Healthcare UK Limited Tel: + 44 (0)800 221441 customercontactuk@gsk.com
{ ViiV Healthcare UK Limited Tel: + 44 (0)800 221441 customercontactuk@gsk.com
ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Ujedinjeno Kraljevstvo
ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Velika Britanija
ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Ujedinjeno Kraljevstvo
ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
ViiV Healthcare UK Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Velika Britanija.
ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom.
ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS Velika Britanija.
Vilanterol is a long-acting beta-2 agonist.
Vilanterol je dugodjelujući beta-2 adrenergički agonist.
Vilanterol is a substrate of cytochrome P450 3A4 (CYP3A4).
Vilanterol je supstrat citokroma P450 3A4 (CYP3A4).
Vildagliptin 50 mg daily +
Vildagliptin 50 mg na dan +
Vildagliptin 50 mg daily + glimepiride (N=132)
Vildagliptin 50 mg na dan + glimepirid (N=132)
Vildagliptin 50 mg twice daily +
Vildagliptin 50 mg dvaput na dan
Vildagliptin 50 mg twice daily +
Vildagliptin 50 mg dvaput na dan +
Vildagliptin 50 mg twice daily + metformin + glimepiride (N=152)
Vildagliptin 50 mg dvaput na dan + metformin + glimepiridin (N=152)
Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults: As monotherapy
Vildagliptin je indiciran u liječenju šećerne bolesti tipa 2 u odraslih: Kao monoterapija
Vildagliptin is not metabolised by CYP 450 enzymes to any quantifiable extent, and accordingly the metabolic clearance of vildagliptin is not anticipated to be affected by co- medications that are CYP 450 inhibitors and/or inducers.
Vildagliptin se ne metabolizira enzimima CYP 450 do bilo kojeg mjerljivog opsega i zbog toga se ne očekuje da na metabolički klirens vildagliptina utječe istodobna primjena lijekova koji su inhibitori i/ili induktori CYP 450.
vildagliptin/metformin hydrochloride
vildagliptin/metforminklorid
Village Moraiya; Taluka Sanand, Ahmedabad – 382213 Gujarat India
Village Moraiya; Taluka: Sanand, Ahmedabad – 382213 Gujarat Indija
Vimizim 1 mg/ml concentrate for solution for infusion
Vimizim 1 mg/ml koncentrat za otopinu za infuziju
Vimizim contains sodium and sorbitol
Vimizim sadrži natrij i sorbitol
Vimizim is supplied as a concentrate for solution for infusion.
Vimizim se isporučuje kao koncentrat za otopinu za infuziju.
Vimizim may be started at as young as an age possible and is intended for long term use.
Vimizim je predviđen za dugotrajnu upotrebu i njegovo davanje treba započeti u što ranijoj dobi.
Vimizim treatment should be supervised by a physician experienced in the management of patients with MPS IVA or other inherited metabolic diseases.
Liječenje Vimizimom mora nadzirati liječnik iskusan u liječenju bolesnika s MPS IV A ili drugim nasljednim bolestima metabolizma.
Vimizim vs.
Vimizim nasuprot placebu
Vimpat 10 mg/ml solution for infusion is a clear, colourless solution.
Vimpat 10 mg/ml otopina za infuziju je bistra, bezbojna otopina.
Vimpat 10 mg/ml solution for infusion Lacosamide
Vimpat 10 mg/ml otopina za infuziju lakozamid
Vimpat 10 mg/ml syrup is a slightly viscous clear, colourless to yellow-brown liquid.
Vimpat 10 mg/ml sirup je blago viskozna, bistra, bezbojna do žutosmeđa tekućina.
Vimpat 10 mg/ml syrup Lacosamide
Vimpat 10 mg/ml sirup lakozamid
Vimpat 100 mg are dark yellow, oval film-coated tablets with a debossed ‘SP’ on one side and ‘100’ on the other side.
Vimpat 100 mg su tamnožute, ovalne filmom obložene tablete s utisnutim 'SP' na jednoj strani i '100' na drugoj strani.
Vimpat 100 mg film-coated tablets Lacosamide
Vimpat 100 mg filmom obložene tablete lakozamid
Vimpat 150 mg are salmon, oval film-coated tablets with a debossed ‘SP’ on one side and ‘150’ on the other side.
Vimpat 150 mg su boje lososa, ovalne filmom obložene tablete s utisnutim 'SP' na jednoj strani i '150' na drugoj strani.
Vimpat 150 mg film-coated tablets Lacosamide
Vimpat 150 mg filmom obložene tablete lakozamid
Vimpat 200 mg are blue, oval film-coated tablets with a debossed ‘SP’ on one side and ‘200’ on the other side.
Vimpat 200 mg su plave, ovalne filmom obložene tablete s utisnutim 'SP' na jednoj strani i '200' na drugoj strani.
Vimpat 200 mg film-coated tablets Lacosamide
Vimpat 200 mg filmom obložene tablete lakozamid
Vimpat 50 mg are pinkish, oval film-coated tablets with a debossed ‘SP’ on one side and ‘50’ on the other side.
Vimpat 50 mg su ružičaste, ovalne filmom obložene tablete s utisnutim 'SP' na jednoj strani i '50' na drugoj strani.
Vimpat 50 mg film-coated tablets Lacosamide
Vimpat 50 mg filmom obložene tablete lakozamid
Vimpat 50 mg film-coated tablets Vimpat 100 mg film-coated tablets Vimpat 150 mg film-coated tablets Vimpat 200 mg film-coated tablets Lacosamide
Vimpat 50 mg filmom obložene tablete Vimpat 100 mg filmom obložene tablete Vimpat 150 mg filmom obložene tablete Vimpat 200 mg filmom obložene tablete lakozamid
Vimpat 600 mg/day was also shown to be effective in controlled adjunctive therapy trials, although the efficacy was similar to 400 mg/day and patients were less likely to tolerate this dose because of CNS- and gastrointestinal-related adverse reactions.
Vimpat se u dozi od 600 mg/dan također pokazao djelotvornim u kontroliranim istraživanjima dopunske terapije, iako je djelotvornost bila slična onoj pri dozi od 400 mg/dan i bolesnici su teže podnosili tu dozu zbog nuspojava SŽS-a i gastrointestinalnog trakta.
Vimpat has been given to you by your doctor to reduce the number of fits.
Vimpat Vam je dao Vaš liječnik za smanjenje broja napadaja.
Vimpat is administered as an infusion into a vein (intravenously) by a healthcare professional.
Zdravstveni djelatnik primjenjuje Vimpat u obliku infuzije u venu (intravenozno).
Vimpat is available in bottles of 200 ml and 465 ml.
Vimpat je dostupan u bocama od 200 ml i 465 ml.
Vimpat is available in packs of 14, 56 and 56 x 1 film-coated tablets and in multipacks comprising 3 cartons, each containing 56 tablets.
Vimpat je dostupan u pakiranjima od 14, 56 i 56 x 1 filmom obloženih tableta i u višestrukim pakiranjima koja se sastoje od 3 kutije od kojih svaka sadrži 56 tableta.
Vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.
Vimpat je indiciran kao dodatna terapija u liječenju parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje kod odraslih i adolescentnih (16-18 godina) bolesnika s epilepsijom.
Vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.
Vimpat je indiciran kao dodatna terapija u liječenju parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje kod odraslih i adolescentnih (16-18) bolesnika s epilepsijom.
Vimpat is not recommended for children and adolescents aged under 16 years.
Vimpat se ne preporučuje za djecu i adolescente mlađe od 16 godina.
Vimpat is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation).
Vimpat se koristi kod oblika epilepsije gdje napadaji na početku zahvaćaju samo jednu stranu mozga, ali se nakon toga mogu proširiti i na veća područja zahvaćajući pritom obje strane mozga (parcijalni nastanak napadaja sa sekundarnom generalizacijom ili bez nje).
Vimpat is used in addition to other antiepileptic medicines.
Vimpat se koristi uz druge antiepileptičke lijekove.
Vimpat may cause dizziness or blurred vision.
Vimpat može uzrokovati omaglicu ili zamućen vid.
Vimpat may cause dizziness, which could increase the risk of accidental injury or a fall.
Vimpat može prouzročiti omaglicu zbog koje može biti povećan rizik slučajne ozljede ili pada.
Vimpat must be administered twice a day, once in the morning and once in the evening, at about the same time each day.
Vimpat se mora primjenjivati dvaput na dan, jednom ujutro i jednom navečer, u otprilike isto vrijeme svakog dana.
Vimpat must be taken twice a day, once in the morning and once in the evening, at about the same time each day.
Vimpat se mora uzimati dvaput na dan, jednom ujutro i jednom navečer, u otprilike isto vrijeme svakog dana.
Vimpat solution for infusion can be administered intravenously without further dilution or can be diluted with sodium chloride 9 mg/ml (0.9%) solution for injection, glucose 50 mg/ml (5%) solution for injection or lactated Ringer’s solution for injection.
Vimpat otopina za infuziju se može primijeniti intravenski bez dodatnog razrjeđivanja ili se može razrijediti s otopinom natrijeva klorida za injekciju 9 mg/ml (0,9%), otopinom glukoze za injekciju 50 mg/ml (5%) ili otopinom Ringerova laktata za injekciju.
Vimpat solution for infusion can be administered without further dilution, or may be diluted with the following solutions: sodium chloride 9 mg/ml (0.9%), glucose 50 mg/ml (5%) or lactated Ringer’s solution.
Vimpat otopina za infuziju se može primjeniti bez daljnjeg razrijeđenja ili se može razrijediti sa sljedećim otopinama: otopina natrijeva klorida 9 mg/ml (0,9%), otopina glukoze 50 mg/ml (5%) ili otopina Ringerova laktata.
Vimpat syrup contains sodium methyl parahydroxybenzoate (E219), which may cause allergic reactions (possibly delayed). ).
Vimpat sirup sadrži natrijev metilparahidroskibenzoat (E219) koji može uzrokovati alergijske reakcije (moguće i reakcije odgođene preosjetljivosti).
Vimpat syrup contains: sorbitol (a type of sugar).
Vimpat sirup sadrži: sorbitol (vrsta šećera).
Vimpat therapy can be initiated with either oral or i.v. administration.
Terapiju Vimpatom moguće je započeti bilo primjenom kroz usta ili u venu.
Vimpat treatment initiation pack contains 4 different packages (one for each tablet strength) with 14 tablets each, for the first 2 to 4 weeks of therapy depending on the patient´s response and tolerability.
Vimpat pakiranje za početak liječenja sadrži 4 različita pakiranja (jedno za svaku jačinu tablete), svako s 14 tableta, za prva 2 do 4 tjedna terapije ovisno o odgovoru i podnošljivosti bolesnika.
Vimpat with alcohol
Vimpat s alkoholom
Vinca Alkaloids (e.g., vincristine
Sulfonilureje (npr. tolbutamid, glipizid, gliburid)
Vinca Alkaloids (e.g., vincristine and vinblastine) [CYP3A4 substrates]
[inhibitor i supstrat CYP3A4]
Vinca alkaloids (vincristine, vinblastine) (P-gp substrates)
Vinka alkaloidi (vinkristin, vinblastin) (Supstrati za P-gp)
Vinca alkaloids: careful monitoring for any occurrence of drug toxicity, and dose reduction if required.
Vinka alkaloidi: paţljivo praćenje radi mogućeg razvoja toksičnosti lijeka i po potrebi smanjenje doze.
Vincamine i.v.
Vinkamin i.v.
Vincristine (used to treat certain types of cancer) since the simultaneous use of vincristine and asparaginase may increase the risk of certain side effects.
Vinkristin (upotrebljava se za liječenje određenih vrsta raka) jer istovremena primjena vinkristina i asparaginaze može povećati rizik od određenih nuspojava.
Vincristine 1.3 mg/ m2 i.v., days 1, 8, 15, 21; Prednisolone 60 mg/ m2/day oral
Vinkristin 1,3 mg/m2 i.v., dani 1, 8, 15, 21; Prednizolon 60 mg/m2/dan peroralno
Vincristine 1.3 mg/m2 i.v., days 1, 8, 15, 21; Prednisolone 60 mg/m2/day oral
daunorubicin 60 mg/m² i.v. (1 h), dani 1-3; vinkristin 1,3 mg/m² i.v., dani 1, 8, 15, 21; prednizolon 60 mg/m²/dan peroralno
Vincristine 1.3 mg/m2 i.v., days 1, 8, 15, 21; Prednisolone 60 mg/m2/day oral
Vinkristin 1,3 mg/m2 i.v., dani 1, 8, 15, 21; Prednizolon 60 mg/m2/dan peroralno
Vincristine 2 mg i.v., days 4, 11;
Vinkristin 2 mg i.v., dani 4, 11;
vincristine, vinblastine
vinkristin, vinblastin
Vincristine, vinblastine (vinca alkaloids)
Vinkristin, vinblastin (vinka alkaloidi)